📣 VC round data is live. Check it out!
- Public Comps
- InfuSystem
InfuSystem Valuation Multiples
Discover revenue and EBITDA valuation multiples for InfuSystem and similar public comparables like MEZOO, Deltex Medical Group, Inogen, Treace Medical Concepts and more.
InfuSystem Overview
About InfuSystem
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.
Founded
2005
HQ

Employees
514
Website
Financials (LTM)
EV
$198M
Valuation Multiples
Start free trialInfuSystem Financials
InfuSystem reported last 12-month revenue of $144M and EBITDA of $32M.
In the same LTM period, InfuSystem generated $81M in gross profit, $32M in EBITDA, and $8M in net income.
Revenue (LTM)
InfuSystem P&L
In the most recent fiscal year, InfuSystem reported revenue of $143M and EBITDA of $31M.
InfuSystem is profitable as of last fiscal year, with gross margin of 56%, EBITDA margin of 22%, and net margin of 5%.
Financial data powered by Morningstar, Inc.
InfuSystem Stock Performance
InfuSystem has current market cap of $177M, and enterprise value of $198M.
Market Cap Evolution
InfuSystem's stock price is $8.77.
InfuSystem share price decreased by 13.4% in the last 30 days, and increased by 51.7% in the last year.
InfuSystem has an EPS (earnings per share) of $0.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $198M | $177M | 0.0% | -13.4% | 0.0% | 51.7% | $0.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInfuSystem Valuation Multiples
InfuSystem trades at 1.4x EV/Revenue multiple, and 6.2x EV/EBITDA.
EV / Revenue (LTM)
InfuSystem Financial Valuation Multiples
As of May 18, 2026, InfuSystem has market cap of $177M and EV of $198M.
InfuSystem has a P/E ratio of 23.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified InfuSystem Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


InfuSystem Margins & Growth Rates
InfuSystem grew revenue by 1% and EBITDA by 4% in the last fiscal year.
In the most recent fiscal year, InfuSystem reported gross margin of 56%, EBITDA margin of 22%, and net margin of 5%.
InfuSystem Margins
InfuSystem Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
InfuSystem Operational KPIs
InfuSystem's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
InfuSystem's Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InfuSystem's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
InfuSystem Competitors
InfuSystem competitors include MEZOO, Deltex Medical Group, Inogen, Treace Medical Concepts, Medinice, EBR Systems, Surgical Science, Apyx Medical, Ilex Medical and Sisram Medical.
Most InfuSystem public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | 25.2x | — | — | |||
| — | — | — | — | |||
| 0.2x | 0.2x | 29.5x | 28.1x | |||
| 0.9x | 0.9x | (49.3x) | (42.3x) | |||
| — | — | (101.5x) | — | |||
| 130.7x | 29.9x | (4.9x) | (4.3x) | |||
| 1.0x | 1.0x | 5.5x | 6.1x | |||
| 3.4x | 3.2x | (46.8x) | (45.6x) | |||
This data is available for Pro users. Sign up to see all InfuSystem competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout InfuSystem
| When was InfuSystem founded? | InfuSystem was founded in 2005. |
| Where is InfuSystem headquartered? | InfuSystem is headquartered in United States. |
| How many employees does InfuSystem have? | As of today, InfuSystem has over 514 employees. |
| Who is the CEO of InfuSystem? | InfuSystem's CEO is Carrie A. Lachance. |
| Is InfuSystem publicly listed? | Yes, InfuSystem is a public company listed on NYSE American. |
| What is the stock symbol of InfuSystem? | InfuSystem trades under INFU ticker. |
| When did InfuSystem go public? | InfuSystem went public in 1992. |
| Who are competitors of InfuSystem? | InfuSystem main competitors include MEZOO, Deltex Medical Group, Inogen, Treace Medical Concepts, Medinice, EBR Systems, Surgical Science, Apyx Medical, Ilex Medical, Sisram Medical. |
| What is the current market cap of InfuSystem? | InfuSystem's current market cap is $177M. |
| What is the current revenue of InfuSystem? | InfuSystem's last 12 months revenue is $144M. |
| What is the current revenue growth of InfuSystem? | InfuSystem revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of InfuSystem? | Current revenue multiple of InfuSystem is 1.4x. |
| Is InfuSystem profitable? | Yes, InfuSystem is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InfuSystem? | InfuSystem's last 12 months EBITDA is $32M. |
| What is InfuSystem's EBITDA margin? | InfuSystem's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of InfuSystem? | Current EBITDA multiple of InfuSystem is 6.2x. |
| How many companies InfuSystem has acquired to date? | InfuSystem hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies InfuSystem has invested to date? | InfuSystem hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to InfuSystem
Lists including InfuSystem
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.